Jose A. Karam

Jose A. Karam is a Professor at The University of Texas MD Anderson Cancer Center, specializing in urologic oncology and surgical oncology. His research focuses on kidney cancer, genitourinary malignancies, and the surgical management of renal tumors, with particular emphasis on non-clear cell renal cell carcinoma subtypes and postoperative surveillance strategies. He leads the randomized phase 3 LITESPARK-022 study investigating adjuvant pembrolizumab plus belzutifan for clear cell renal cell carcinoma. His recent work also explores circulating tumor DNA as a real-time biomarker in marker-negative germ cell tumors and percutaneous cryoablation for T1b renal tumors. His clinical and translational research integrates pathology, nephrology, and cancer care to advance precision oncology and improve outcomes for patients with genitourinary cancers.